A Study of LUMIGAN® RC in the Clinical Setting

Allergan

Status and phase: Completed; Phase 4

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Treatments: Drug: Bimatoprost 0.01%

Study type: Interventional

Funder types: Industry

Identifiers

NCT01833741

CLEAR

Details and patient eligibility

About

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

Enrollment: 1,137 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Elevated IOP due to either primary open-angle glaucoma or ocular hypertension
• Determined by the treating physician to require treatment with LUMIGAN® RC

Exclusion criteria

• None

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,137 participants in 1 patient group

Bimatoprost 0.01%

Experimental group

Description:

Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.

Treatment:

Drug: Bimatoprost 0.01%